Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
Study Details
Study Description
Brief Summary
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
Not required
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: SPD489
|
Drug: SPD489
Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks [Basline and 52 weeks]
- Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks [Baseline and 52 weeks]
- Columbia-Suicide Severity Rating Scale (C-SSRS) [Up to 52 weeks]
- Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks [Baseline and 52 weeks]
Secondary Outcome Measures
- Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks [Baseline and 52 weeks]
- Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks [Baseline and 52 weeks]
- Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale [Baseline and week 52]
- Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale [Up to 52 weeks]
- Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks [Baseline and 52 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 to 65 years of age
-
Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
-
Fixed home/place of residence and can be reached by telephone
-
On a stable dose of antipsychotic medications
-
Able to swallow capsules
Exclusion Criteria:
-
-Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
-
Treated with clozapine in past 30 days
-
Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
-
History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
-
Uncontrolled hypertension
-
History of thyroid disorder that has not been stabilized on thyroid medication
-
Glaucoma
-
Pregnant or nursing
-
Subject has received an investigational product or participated in a clinical study within 30 days
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | SP Research PLLC/Oklahoma Clinical Research Center | Oklahoma City | Oklahoma | United States | 73112 |
2 | CRI Lifetree | Philadelphia | Pennsylvania | United States | 19139 |
Sponsors and Collaborators
- Shire
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SPD489-336
- 2012-003920-18
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Period Title: Overall Study | |
STARTED | 0 |
COMPLETED | 0 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Overall Participants | 0 |
Age () [] | |
<=18 years | |
Between 18 and 65 years | |
>=65 years | |
Sex: Female, Male () [] | |
Female | |
Male | |
Region of Enrollment () [] |
Outcome Measures
Title | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks |
---|---|
Description | |
Time Frame | Basline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Columbia-Suicide Severity Rating Scale (C-SSRS) |
---|---|
Description | |
Time Frame | Up to 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale |
---|---|
Description | |
Time Frame | Baseline and week 52 |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale |
---|---|
Description | |
Time Frame | Up to 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Title | Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks |
---|---|
Description | |
Time Frame | Baseline and 52 weeks |
Outcome Measure Data
Analysis Population Description |
---|
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized |
Arm/Group Title | SPD489 |
---|---|
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks |
Measure Participants | 0 |
Adverse Events
Time Frame | ||
---|---|---|
Adverse Event Reporting Description | Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized | |
Arm/Group Title | SPD489 | |
Arm/Group Description | SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks | |
All Cause Mortality |
||
SPD489 | ||
Affected / at Risk (%) | # Events | |
Total | / (NaN) | |
Serious Adverse Events |
||
SPD489 | ||
Affected / at Risk (%) | # Events | |
Total | 0/0 (NaN) | |
Other (Not Including Serious) Adverse Events |
||
SPD489 | ||
Affected / at Risk (%) | # Events | |
Total | 0/0 (NaN) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.
Results Point of Contact
Name/Title | Study Director |
---|---|
Organization | Shire |
Phone | +1 866 842 5335 |
ClinicalTransparency@shire.com |
- SPD489-336
- 2012-003920-18